AI assistant
Passage BIO, Inc. — Director's Dealing 2020
Mar 2, 2020
34849_dirs_2020-03-02_0fa9f663-b4c6-4eaf-beb0-c7e5c3b0693a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2020-02-27
Reporting Person: SQUINTO STEPHEN P (Director, Head of Research and Dev)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-27 | Employee Stock Option (Right to Buy) | $18.00 | A | 185776 | Acquired | 2030-02-27 | Common Stock (185776) | Direct |
| 2020-02-27 | Director Stock Option (Right to Buy) | $18.00 | A | 33836 | Acquired | 2030-02-27 | Common Stock (33836) | Direct |
Footnotes
F1: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date.
F2: The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.